Sarepta price target lowered to $179 from $210 at BofA
BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the departure of Peter Marks from the FDA’s Center for Biologics ...
BioSpace3h
Biotech’s ‘Worst Fear’ Comes True as FDA’s Marks Departs, Sending Shares Tumbling
Already reeling from years of market chaos, the announced departure of CBER chief Peter Marks sent a ripple across biopharma ...
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra
Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the ...
BioPharma Dive22h
Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
Investor's Business Daily on MSN23h
Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'
For 13 years, Marks led the FDA's Center for Biologics Evaluation and Research, the department in charge of reviewing and approving vaccines, genetic medicines and cell therapies.Please watch the ...